Literature DB >> 7919327

Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo.

P Aukrust1, S S Frøland, N B Liabakk, F Müller, I Nordøy, C Haug, T Espevik.   

Abstract

We investigated the in vivo effects of one bolus injection (400 mg/kg) of intravenous immunoglobulin (IVIG) on a number of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist (IL-1Ra) in plasma in 12 patients with primary hypogammaglobulinemia. A significant and rapid increase in plasma levels of IL-6, IL-8, and tumor necrosis factor alpha (TNF alpha) was seen within 1 hour after IVIG infusion. This increase was accompanied by a more prolonged elevation in levels of both types of soluble TNF receptors (sTNFRs), which remained elevated throughout the study period (44 hours) although they reached peak levels within 1 hour. After an initial increase in the ratio between TNF alpha and sTNFRs, this ratio decreased to values significantly lower than baseline values 20 and 44 hours postinfusion with approximately 600-fold molar excess of sTNFRs to TNF alpha (trimer). Although only a modest but statistically significant increase in plasma levels of IL-1 beta was seen, IVIG infusion was followed by a marked increase in plasma levels of IL-1Ra with 1,000-fold molar excess of IL-1Ra to IL-1 beta in some patients. The demonstrated effects of IVIG infusion on the cytokine network, particularly the induction of IL-1Ra and sTNFRs release, might be important for the therapeutic effects of IVIG in several immune-mediated disorders.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7919327

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  Expression of IL-8 in Kawasaki disease.

Authors:  T Asano; S Ogawa
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

Review 2.  Immunomodulatory action of intravenous immunoglobulin.

Authors:  W A C Sewell; S Jolles
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

3.  Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma.

Authors:  Mark P Purdue; Qing Lan; Rachel Bagni; William G Hocking; Dalsu Baris; Douglas J Reding; Nathaniel Rothman
Journal:  Cancer Res       Date:  2011-06-01       Impact factor: 12.701

4.  A comparative study of the in vitro immunomodulatory activity of human intact immunoglobulin (7S IVIG), F(ab')2 fragments (5S IVIG) and Fc fragments. Evidence for post-transcriptional IL-2 modulation.

Authors:  D Nachbaur; M Herold; B Eibl; H Glassl; H Schwaighofer; C Huber; A Gächter; M Pichl; D Niederwieser
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

Review 5.  Clinical uses of intravenous immunoglobulin.

Authors:  S Jolles; W A C Sewell; S A Misbah
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

Review 6.  Basic principles of intravenous immunoglobulin (IVIg) treatment.

Authors:  Martin Stangel; Refik Pul
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

7.  Magnitude and Quality of Cytokine and Chemokine Storm during Acute Infection Distinguish Nonprogressive and Progressive Simian Immunodeficiency Virus Infections of Nonhuman Primates.

Authors:  Sheila M Keating; John W Heitman; Shiquan Wu; Xutao Deng; Andrea R Stacey; Roland C Zahn; Maurus de la Rosa; Samantha L Finstad; Jeffrey D Lifson; Michael Piatak; Marie-Claire Gauduin; Benedikt M Kessler; Nicola Ternette; Angela Carville; R Paul Johnson; Ronald C Desrosiers; Norman L Letvin; Persephone Borrow; Philip J Norris; Joern E Schmitz
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

8.  Recommendations for the use of albumin and immunoglobulins.

Authors:  Giancarlo Maria Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossettias
Journal:  Blood Transfus       Date:  2009-07       Impact factor: 3.443

9.  Autoantibodies to the delta-opioid receptor function as opioid agonists and display immunomodulatory activity.

Authors:  Parvathi Ranganathan; Hao Chen; Miranda K Adelman; Samuel F Schluter
Journal:  J Neuroimmunol       Date:  2009-10-30       Impact factor: 3.478

10.  Human intravenous immunoglobulin (IVIG) preparations degranulate human neutrophils in vitro.

Authors:  J L Teeling; E R De Groot; A J Eerenberg; W K Bleeker; G Van Mierlo; L A Aarden; C E Hack
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.